Ide, Akira
Nozaki-Taguchi, Natsuko
Sato, Shin
Saito, Kei
Sato, Yasunori
Isono, Shiroh
Funding for this research was provided by:
Japan Society for the Promotion of Science (20H03774)
Article History
Received: 17 November 2021
Accepted: 31 May 2022
First Online: 3 June 2022
Declarations
:
: Ethical approval for this study (Ethical Committee number: 1650) was provided by the Ethical Committee of Chiba University Graduate School of Medicine, Chiba, Japan (Chairperson: Prof. Masaomi Iyo) on 25/11/2013 and revised on July 2017. The study protocol was registered in University hospital Medical information network Clinical trial Registry (UMIN000012495, 05/12/2013: ExternalRef removed). This prospective, double-blinded, and randomized placebo-controlled study with parallel groups from December 2013 to March 2014, and from November 2017 to February 2019 was performed at Chiba University Hospital, Chiba, Japan. Since the study was not completed as originally planned due to absence of the primary investigator (A.I.) at Chiba University Hospital for 3 years, it was restarted after the interruption. All the patients who participated in this study voluntarily signed written informed consent forms after the aim and potential risks of the study were fully explained to each. This study complied with the Declaration of Helsinki and adhered to the applicable CONSORT guidelines.
: Not applicable.
: Dr. Isono received payments for his lectures from MSD Japan that distributes rocuronium and sugammadex in Japan. Other authors attest that no conflict of interest exists to perform this study and write this manuscript.